{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:26:27Z","timestamp":1791926787216,"version":"4.3.4"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Primary aldosteronism (PA), a leading cause of secondary hypertension, remains profoundly underdiagnosed and, contributes to vast preventable cardiovascular morbidity and mortality worldwide. Affecting 4.5\u201320% of patients with high blood pressure, PA drives excess aldosterone production, substantially elevating risks of heart failure, stroke, atrial fibrillation, and renal damage, with untreated cases facing 10\u201320% higher mortality rates over 5\u201310 years compared to essential hypertension. Adrenalectomy for unilateral PA driven by somatic mutations (e.g.,\n                    <jats:italic>KCNJ5<\/jats:italic>\n                    ) offers markedly superior outcomes over medical therapy, yielding an absolute risk reduction in all-cause mortality that rivals or exceeds many major cardiovascular surgeries and greatly improves quality of life by resolving hypertension, hypokalemia, and associated symptoms. Advanced surgical approaches such as mini back scope adrenalectomy (posterior retroperitoneoscopic) minimize risks and enable precise, function-preserving surgery. Yet, current surgical rates, ranging from 1.2 to 8.4 per million across countries like Sweden, Taiwan, France, UK, Germany, and USA, represent less than 4% of the optimal rate of 212 operations\/million. Achieving optimal adrenalectomy rates requires increasing surgical capacity 25\u2013170-fold, potentially saving 5,627 lives annually in the USA alone. Disparities arise from diagnostic barriers, including underutilization of aldosterone-to-renin ratio screening, complex confirmatory testing, and limited access to adrenal vein sampling and high-volume adrenal surgeons. This perspective highlights PA\u2019s severe burden, compares adrenalectomy\u2019s efficacy to major cardiac and vascular operations, and examines international caseload variations linked to research infrastructure, PA guidelines, and access to high-volume centers. We strongly urge enhanced PA screening, improved case detection, diagnostic workflows, and expanded surgical access to avert this silent epidemic.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2025.1737160","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:12:39Z","timestamp":1765170759000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Primary aldosteronism: adrenalectomy could save more lives"],"prefix":"10.3389","volume":"16","author":[{"given":"Tobias","family":"Carling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio R.","family":"Faucz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0375","article-title":"Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis","volume":"187","author":"Chen","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism - a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01981-6","article-title":"Primary aldosteronism is a clinical issue that should not be underestimated anymore","volume":"46","author":"Parasiliti-Caprino","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09710-8","article-title":"Overview of the 2022 WHO classification of adrenal cortical tumors","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e240296","DOI":"10.1530\/ERC-24-0296","article-title":"Improved and individualized approach to adrenal surgery","volume":"32","author":"Carling","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18761","article-title":"Primary aldosteronism: where are we now? Where to from here","volume":"79","author":"Funder","year":"2022","journal-title":"Hypertension"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102791","article-title":"Global and regional prevalence and cardiovascular risk of primary aldosteronism: a systematic review and meta-analysis","volume":"49","author":"Huang","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11886-019-1185-x","article-title":"Primary aldosteronism: cardiovascular outcomes pre- and post-treatment","volume":"21","author":"Hundemer","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.25104","article-title":"Adrenalectomy versus medical therapy in primary aldosteronism: A meta-analysis of long-term cardiac remodeling and function: medical versus adrenalectomy treatment compared in hyperaldosteronism (MATCH) study","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.22642","article-title":"Clinical management of primary aldosteronism: an update","volume":"81","author":"Rossi","year":"2024","journal-title":"Hypertension"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003813","article-title":"Impact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry","volume":"42","author":"Araujo-Castro","year":"2024","journal-title":"J Hypertens"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e93136","DOI":"10.1172\/jci.insight.93136","article-title":"Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism","volume":"2","author":"Arlt","year":"2017","journal-title":"JCI Insight"},{"key":"B16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/ejendo\/lvaf007","article-title":"Mild autonomous cortisol secretion in patients with aldosterone-producing adenoma and risk for cardiac remodeling and diastolic dysfunction","volume":"192","author":"Tsai","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.855326","article-title":"Tailored approach in adrenal surgery: retroperitoneoscopic partial adrenalectomy","volume":"13","author":"Alesina","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.7193","article-title":"Retroperitoneal endoscopic adrenalectomy is safe and effective (Br J Surg 2010; 97:1667-1672)","volume":"97","author":"Carling","year":"2010","journal-title":"Br J Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e038714","DOI":"10.1161\/JAHA.124.038714","article-title":"Major adverse cardiovascular events in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: A systematic review and meta-analysis","volume":"14","author":"Huang","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad654","article-title":"Time to benefit of surgery vs targeted medical therapy for patients with primary aldosteronism: A meta-analysis","volume":"109","author":"Samnani","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00308-5","article-title":"Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.21895","article-title":"Mortality in patients with primary aldosteronism: A swedish nationwide study","volume":"80","author":"Gkaniatsa","year":"2023","journal-title":"Hypertension"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf007","article-title":"KCNJ5 somatic mutations are associated with better long-term outcomes in patients with unilateral primary aldosteronism","volume":"110","author":"Chan","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2149","article-title":"A meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma","volume":"100","author":"Lenzini","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00253-4","article-title":"Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study","volume":"10","author":"Williams","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4167","article-title":"Primary aldosteronism and ARMC5 variants","volume":"100","author":"Zilbermint","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"Mack","year":"2019","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715955","article-title":"Open versus endovascular repair of abdominal aortic aneurysm","volume":"380","author":"Lederle","year":"2019","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61197-X","article-title":"10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial","volume":"376","author":"Halliday","year":"2010","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/s0140-6736(94)91963-1","article-title":"Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration","volume":"1994","author":"Yusuf","year":"8922","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-019-05265-8","article-title":"Outcomes after surgery for unilateral dominant primary aldosteronism in Sweden","volume":"44","author":"Sellgren","year":"2020","journal-title":"World J Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-21-0836","article-title":"Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments","volume":"186","author":"Wu","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2025.10.004","article-title":"Adrenalectomy is underused: a call to reduce mortality","author":"Carling","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"B36","article-title":"Scandinavian Quality Register for Thyroid, Parathyroid and Adrenal Surgery (SQRTPA) (2024), \u00c5rsrapport 2024","year":""},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006026","article-title":"Surgery for primary aldosteronism in France from 2010 to 2020 - results from the french-speaking association of endocrine surgery (AFCE): eurocrine study group","volume":"278","author":"Vignaud","year":"2023","journal-title":"Ann Surg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab142","article-title":"Volume-outcome relationship for adrenalectomy: analysis of an administrative dataset for the Getting It Right First Time Programme","volume":"108","author":"Gray","year":"2021","journal-title":"Br J Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2021.10.065","article-title":"Factors associated with postoperative complications and costs for adrenalectomy in benign adrenal disorders","volume":"171","author":"Sung","year":"2022","journal-title":"Surgery"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1555572","article-title":"Screening for primary aldosteronism in 1,181 Swedish primary care patients with hypertension","volume":"16","author":"Makhnov","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2023.05.032","article-title":"Treatment of primary aldosteronism: Clinical practice guidelines of the Taiwan Society of Aldosteronism","author":"Tseng","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-025-02101-6","article-title":"Speculating suitability of partial adrenalectomy for lateralized primary aldosteronism: With emphasis on partial and complete success as optimistic outcomes","volume":"48","author":"Lee","year":"2025","journal-title":"Hypertens Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00104-020-01277-6","article-title":"EUROCRINE(R): adrenal surgery 2015-2019- surprising initial results","volume":"92","author":"Staubitz","year":"2021","journal-title":"Chirurg"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf290","article-title":"A systematic review supporting the endocrine society clinical practice guideline on management of primary aldosteronism","volume":"110","author":"Farah","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa952","article-title":"Approach to the patient with primary aldosteronism: utility and limitations of adrenal vein sampling","volume":"106","author":"Turcu","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf204","article-title":"Adrenal vein sampling in primary aldosteronism-is the gold standard losing its luster","volume":"110","author":"Deinum","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ejendo\/lvaf117","article-title":"Expert Consensus on the Primary Aldosteronism Severity Classification and its strategic application in indicating adrenal venous sampling","volume":"193","author":"Murakami","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e060779","DOI":"10.1136\/bmjopen-2022-060779","article-title":"CXCR4-directed [(68)Ga]Ga-PentixaFor PET\/CT versus adrenal vein sampling performance: a study protocol for a randomised two-step controlled diagnoStic Trial Ultimately comparing hypertenSion outcome in primary aldosteronism (CASTUS)","volume":"12","author":"Chaman Baz","year":"2022","journal-title":"BMJ Open"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1533295","article-title":"The value of targeted CXCR4 (18)F-AlF-NOTA-pentixafor PET\/CT for subtyping primary aldosteronism","volume":"16","author":"Peng","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41591-022-02114-5","article-title":"(11)C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial","volume":"29","author":"Wu","year":"2023","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae747","article-title":"Comparison of different diagnostic criteria of 68Ga-pentixafor PET\/CT for the classification of primary aldosteronism","volume":"110","author":"Zhang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02755-7","article-title":"Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial","volume":"405","author":"Argentesi","year":"2025","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad026","article-title":"Treating primary aldosteronism-induced hypertension: novel approaches and future outlooks","volume":"45","author":"Mullen","year":"2024","journal-title":"Endocr Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2508629","article-title":"Phase 2a study of baxdrostat in primary aldosteronism","volume":"393","author":"Turcu","year":"2025","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1056\/NEJMc2512324","article-title":"More about the phase 2a study of baxdrostat in primary aldosteronism","volume":"393","author":"Carling","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1737160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:12:39Z","timestamp":1765170759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1737160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":55,"alternative-id":["10.3389\/fendo.2025.1737160"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1737160","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1737160"}}